Research programme: tyrosine kinase inhibitors - pSivida

Drug Profile

Research programme: tyrosine kinase inhibitors - pSivida

Alternative Names: Durasert™ TKI insert

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator pSivida
  • Class
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Wet age-related macular degeneration

Most Recent Events

  • 07 Feb 2017 Research programme: tyrosine kinase inhibitors - pSivida is available for licensing as of 07 Feb 2017. http://www.psivida.com
  • 05 Jul 2016 Preclinical trials in Wet age-related macular degeneration in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top